a Department of Oncology , King Faisal Specialist Hospital and Research Center , Jeddah , Kingdom of Saudi Arabia.
b College of Medicine , Al-Faisal University , Riyadh , Kingdom of Saudi Arabia.
Expert Opin Biol Ther. 2016 Jun;16(6):739-45. doi: 10.1080/14712598.2016.1180362. Epub 2016 May 3.
This meta-analysis evaluated the effect of single agent brentuximab vedotin (BV) in patients with relapsed/refractory Hodgkin lymphoma (HL).
A systematic literature search was performed and included studies published from 1(st) January 2012 to 1(st) July 2015 investigating BV in patients with relapsed/refractory HL. Data was extracted and reviewed by two investigators then analyzed using the comprehensive meta-analysis version 3 software.
22 out of 4048 screened records met the eligibility criteria. These records included 903 patients. The median age of the cohort was 31 years (range: 26-45). 86% received ≥ 3 previous lines of systemic therapy. 529 (58.7%) and 232 (25.7%) underwent high dose chemotherapy and autologous and/or allogeneic stem transplantation prior of BV respectively. The overall response rate to BV was 62.7% (range: 30-100%). The complete response, partial response, stable disease and progressive disease rates were 31.8%, 35.1%, 19.5% and 11.7% respectively. The one year progression free survival and estimated one year overall survival were 47.6% and 79.5% respectively.
In this largest published pooled cohort, BV produces high responses with encouraging progression free and overall survival in relapsed/refractory HL patients. Our results enhance the role of BV in heavily pretreated HL patients.
本荟萃分析评估了单药 Brentuximab Vedotin（BV）在复发/难治性霍奇金淋巴瘤（HL）患者中的疗效。
进行了系统的文献检索，纳入了 2012 年 1 月 1 日至 2015 年 7 月 1 日期间研究 BV 在复发/难治性 HL 患者中的应用的研究。由两名研究者提取和审查数据，然后使用综合荟萃分析版本 3 软件进行分析。
在 4048 份筛选记录中，有 22 份符合纳入标准。这些记录包括 903 名患者。队列的中位年龄为 31 岁（范围：26-45）。86%的患者接受了≥3 线系统治疗。529 例（58.7%）和 232 例（25.7%）分别在接受 BV 治疗前接受了高剂量化疗和自体及/或异基因干细胞移植。BV 的总体缓解率为 62.7%（范围：30-100%）。完全缓解、部分缓解、稳定疾病和进展疾病的比例分别为 31.8%、35.1%、19.5%和 11.7%。1 年无进展生存率和估计 1 年总生存率分别为 47.6%和 79.5%。
在这项最大的已发表汇总队列研究中，BV 在复发/难治性 HL 患者中产生了高反应率，且无进展生存和总生存情况令人鼓舞。我们的结果增强了 BV 在经大量预处理的 HL 患者中的作用。
